Ekso Bionics (EKSO) – Research Analysts’ Weekly Ratings Updates

Ekso Bionics (NASDAQ: EKSO) recently received a number of ratings updates from brokerages and research firms:

• 3/11/2025 – Ekso Bionics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 3/4/2025 – Ekso Bionics had its price target lowered by analysts at Lake Street Capital from $2.00 to $1.00. They now have a “buy” rating on the stock.
• 3/4/2025 – Ekso Bionics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
• 3/3/2025 – Ekso Bionics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 2/23/2025 – Ekso Bionics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 2/15/2025 – Ekso Bionics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 2/7/2025 – Ekso Bionics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 1/30/2025 – Ekso Bionics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 1/22/2025 – Ekso Bionics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.

Ekso Bionics Trading Up 1.7 %

EKSO stock opened at $0.43 on Tuesday. The business has a fifty day moving average price of $0.57 and a 200 day moving average price of $0.78. Ekso Bionics Holdings, Inc. has a fifty-two week low of $0.34 and a fifty-two week high of $1.53. The stock has a market capitalization of $10.70 million, a price-to-earnings ratio of -0.66 and a beta of 1.43. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.81 and a quick ratio of 2.14.

Ekso Bionics (NASDAQ:EKSO) last released its quarterly earnings results on Monday, March 3rd. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.07). Ekso Bionics had a negative net margin of 62.95% and a negative return on equity of 83.09%. The business had revenue of $5.09 million for the quarter, compared to analyst estimates of $5.05 million. Analysts expect that Ekso Bionics Holdings, Inc. will post -0.48 EPS for the current fiscal year.

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.